A practical reference on thymus extract: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Medical Oncology, which involves treatment of cancer with chemicals, biological products and immunotherapy Radiation Oncology, or the careful use of high-energy radiation to treat cancer The goal of radiation therapy is to deliver a precisely measured dose to the cancerous tumor, while protecting normal tissue around the tumor Hematology, or the diagnosis and treatment of diseases of the blood and blood forming organs Genetic Testing, a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders Clinical Trials, studies that evaluate the effectiveness of new drugs and strategies In addition to providing cancer care, SOMC also holds annual breast cancer awareness events (referred to as “pink outs” or by the name “Paint It Pink”) to coincide with October's designation as Breast Cancer Awareness Month. The events have received positive community feedback and helped raise money for the SOMC Breast Cancer Compassion Fund. The Breast Cancer Compassion Fund provides money to help support breast cancer patients with expenses such as utilities, medications, transportation and common necessities needed during cancer care. In 2012, Portsmouth Mayor David Malone declared October 20 “Paint It Pink Day.” That year's event also grew to include a 5k run/walk. SOMC has also worked to raise breast cancer awareness by creating a “Pink Glove Dance” YouTube video featuring local residents and hospital employees.
=== Mitral regurgitation === Patients with mitral regurgitation may present with heart failure symptoms, such as dyspnea on exertion, orthopnea and paroxysmal nocturnal dyspnea, palpitations, or pulmonary edema. On auscultation of a patient with mitral stenosis, there may be a holosystolic murmur at the apex, radiating to the back or clavicular area, a third heart sound, and a loud, palpable P2, heard best when lying on the left side. Patients also commonly have atrial fibrillation. Patients may have a laterally displaced apex beat, often with heave In acute cases, the murmur and tachycardia may be only distinctive signs.
More generally, RNase A is unusually polar or, rather, unusually lacking in hydrophobic groups, especially aliphatic ones. This may account for its need of four disulfide bonds to stabilize its structure. The low hydrophobic content may also serve to reduce the physical repulsion between highly charged groups (its own and those of its substrate RNA) and regions of low dielectric constant (the nonpolar residues). The N-terminal α-helix of RNase A (residues 3–13) is connected to the rest of RNase A by a flexible linker (residues 16–23). As shown by F. M. Richards, this linker may be cleaved by subtilisin between residues 20 and 21 without causing the N-terminal helix to dissociate from the rest of RNase A. The peptide-protein complex is called "RNase S", the peptide (residues 1-20) is called the "S-peptide" and the remainder (residues 21–124) is called the "S-protein". The dissociation constant of the S-peptide for the S-protein is roughly 30 pM; this tight binding can be exploited for protein purification by attaching the S-peptide to the protein of interest and passing a mixture over an affinity column with bound S-protein. [A smaller C-peptide (residues 1–13) also works.] The RNase S model system has also been used for studying protein folding by coupling folding and association. The S-peptide was the first peptide from a native protein shown to have (flickering) secondary structure in isolation (by Klee and Brown in 1967). RNase A cleaves specifically after pyrimidine nucleotides.
Glycolysis and glycogenolysis defects: McArdle's disease, phosphofructokinase deficiency, glycogen storage diseases VIII, IX, X and XI Lipid metabolism defects: carnitine palmitoyltransferase I and II deficiency, deficiency of subtypes of acyl CoA dehydrogenase (LCAD, SCAD, MCAD, VLCAD, 3-hydroxyacyl-coenzyme A dehydrogenase deficiency), thiolase deficiency Mitochondrial myopathies: deficiency of succinate dehydrogenase, cytochrome c oxidase and coenzyme Q10 Others: glucose-6-phosphate dehydrogenase deficiency, myoadenylate deaminase deficiency and muscular dystrophies
Sources: en.wikipedia.org
==== Monosaccharide reduction ==== There are many ways silver nanoparticles can be synthesized; one method is through monosaccharides. This includes glucose, fructose, maltose, maltodextrin, etc., but not sucrose. It is also a simple method to reduce silver ions back to silver nanoparticles as it usually involves a one-step process. There have been methods that indicated that these reducing sugars are essential to the formation of silver nanoparticles. Many studies indicated that this method of green synthesis, specifically using Cacumen platycladi extract, enabled the reduction of silver. Additionally, the size of the nanoparticle could be controlled depending on the concentration of the extract. The studies indicate that the higher concentrations correlated to an increased number of nanoparticles. Smaller nanoparticles were formed at high pH levels due to the concentration of the monosaccharides. Another method of silver nanoparticle synthesis includes the use of reducing sugars with alkali starch and silver nitrate. The reducing sugars have free aldehyde and ketone groups, which enable them to be oxidized into gluconate. The monosaccharide must have a free ketone group because in order to act as a reducing agent it first undergoes tautomerization. In addition, if the aldehydes are bound, it will be stuck in cyclic form and cannot act as a reducing agent. For example, glucose has an aldehyde functional group that is able to reduce silver cations to silver atoms and is then oxidized to gluconic acid. The reaction for the sugars to be oxidized occurs in aqueous solutions.
==== Empire of Japan ==== Under the constitution of the Empire of Japan, the Imperial Diet (Teikoku-gikai) was a bicameral legislature of two houses, generally equal in legislative authority, and while the members of both houses received the same financial compensation - from 1920 and 1947, ¥7500 for the two presidents, ¥4500 for the two vice-presidents, ¥3000 for all other members of both houses, except Imperial princes, dukes and marquesses—their status was different by definition: The upper house consisted mainly of hereditary nobles and lifetime-appointed peers, the lower house of elected commoners. In the First Imperial Diet in 1890, there were initially 551 members of the Imperial Diet (Teikoku-gikai giin, 帝国議会議員, or in contemporaneous script 帝國議會議員): 251 members of the House of Peers (Kizokuin giin, 貴族院議員) and 300 members of the House of Representatives (Shūgiin giin); of the House of Peers members, 10 were members of the Imperial family, 31 were hereditary members from the two upper nobility ranks, 104 were members elected in mutual elections from the three lower nobility ranks, 61 were lifetime-appointed members (many of these from the bureaucracy) and 45 were members elected by the 15 top taxpayers in each of the 45 prefectures.
In the United States, an all-out effort for making atomic weapons was begun in late 1942. This work was taken over by the U.S. Army Corps of Engineers in 1943, and known as the Manhattan Engineer District. The top-secret Manhattan Project, as it was colloquially known, was led by General Leslie R. Groves. Among the project's dozens of sites were: Hanford Site in Washington, which had the first industrial-scale nuclear reactors and produced plutonium; Oak Ridge, Tennessee, which was primarily concerned with uranium enrichment; and Los Alamos, in New Mexico, which was the scientific hub for research on bomb development and design. Other sites, notably the Berkeley Radiation Laboratory and the Metallurgical Laboratory at the University of Chicago, played important contributing roles. Overall scientific direction of the project was managed by the physicist J. Robert Oppenheimer. In July 1945, the first atomic explosive device, dubbed "The Gadget", was detonated in the New Mexico desert in the Trinity test. It was fueled by plutonium created at Hanford. In August 1945, two more atomic devices – "Little Boy", a uranium-235 bomb, and "Fat Man", a plutonium bomb – were used against the Japanese cities of Hiroshima and Nagasaki.
Han Chinese can be divided into subgroups, based on the variety of Chinese that they speak. Waves of migration have occurred throughout China's long history and vast geographical expanse, engendering the emergence of Han Chinese subgroups found throughout the regions of modern China today, with distinct regional features.
== Analytics == It is possible to determine the content of usnic acid in lichen extract using reversed-polarity capillary zone electrophoresis or high performance liquid chromatography analysis. A spot test using anisaldehyde reagent was developed to detect usnic acid in lichens, producing a distinctive magenta color reaction that works reliably in the presence of most other lichen substances and can aid in identification, particularly in species where visual detection of usnic acid's natural pale yellow color is difficult.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.